PHOENIXVILLE, PA — Facet Life Sciences has been selected as the U.S. regulatory partner for Cybin Inc., a neuropsychiatry company focused on innovative mental health treatments. This collaboration aims to accelerate the development and approval of next-generation therapies for disorders such as Major Depressive Disorder, Generalized Anxiety Disorder, and central nervous system conditions.
Facet Life Sciences will provide comprehensive regulatory guidance to Cybin, leveraging its expertise to steer the company’s breakthrough therapies through the U.S. Food and Drug Administration (FDA) review process. This partnership will support Cybin’s pipeline, which includes CYB003, a deuterated psilocin program currently in Phase 3 development for major depressive disorder. CYB003, which received FDA Breakthrough Therapy Designation, represents significant progress in addressing the unmet needs of mental health patients.
Ken VanLuvanee, CEO of Facet Life Sciences, highlighted the importance of the partnership, stating, “We are excited to collaborate with Cybin as their regulatory partner, supporting their mission to redefine mental health treatment through innovation.”
Cybin’s innovative approach to therapeutics, combined with Facet’s regulatory expertise, could pave the way for safer, more effective treatments for individuals living with complex mental health challenges. This partnership signals a promising step forward in the field of neuropsychiatry.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.